In-Silico evaluation of Anti-Leishmanial compounds of selected pharmacophore

  • Sindhuprava Rana Department of Biotechnology, Sri Satya Sai University of Technology & Medical Sciences, Sehore-466001
  • R Sivaperumal Department of Biotechnology, Sri Satya Sai University of Technology & Medical Sciences, Sehore-466001

Abstract

In this study, out of sixteen compounds, only thirteen compounds have shown hydrogen bonding with the modeled cathepsin B protein of L donovani, remaining compound (C1D13416238, Posaconazole. and CID 6082033) did not show any hydrogen bonding with ligands. So, these 13 compounds which show hydrogen bonding with modeled protein could be considered as most potent lead compounds having inhibitory activity at either promastigote stage or amastigote stage of Leishmania donovani. Few compounds demonstrated better docking score to either AutoDock4.0 or GOLD v2.l but some compound did not show any hydrogen bonding with modeled protein in either docking software tool. Thus, it could be concluded that generated experimental compounds could have potential as pharmacological tool against Visceral Leishmaniasis.


Keywords: Cysteine Protease, Vinyl Hydrazide, Antileishmanial Drugs, Licochalcone, Visceral Leishmaniasis.

Downloads

Download data is not yet available.

Author Biographies

Sindhuprava Rana, Department of Biotechnology, Sri Satya Sai University of Technology & Medical Sciences, Sehore-466001

Department of Biotechnology, Sri Satya Sai University of Technology & Medical Sciences, Sehore-466001

R Sivaperumal, Department of Biotechnology, Sri Satya Sai University of Technology & Medical Sciences, Sehore-466001

Department of Biotechnology, Sri Satya Sai University of Technology & Medical Sciences, Sehore-466001

References

1. Chappuis F et al., “Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?,” Nat. Rev. Microbiol., 2007; 5(11):S7.
2. Lukeš J, Skalickỳ T, Tỳč J, Votỳpka J, Yurchenko V, “Evolution of parasitism in kinetoplastid flagellates,” Mol. Biochem. Parasitol., 2014; 195(2):115–122.
3. Andersen JF, Pham VM, Meng Z, Champagne DE, Ribeiro JM, “Insight into the Sialome of the Black Fly, Simulium vittatum,” J. Proteome Res. 2009; 8(3):1474–1488.
4. W. H. O., Leishmaniasis. Fact sheet. Updated March 2016. 2016.
5. Pearson RD, de Queiroz Sousa A, “Clinical spectrum of leishmaniasis,” Clin. Infect. Dis., 1996; 1–11.
6. Chang CS, Chang KP, “Heme requirement and acquisition by extracellular and intracellular stages of Leishmania mexicana amazonensis,” Mol. Biochem. Parasitol., 1985; 16(3):267–276.
7. Petersen CA, Greenlee MHW, “Neurologic manifestations of Leishmania spp. infection,” J. Neuroparasitology, 2011; 2.
Statistics
60 Views | 66 Downloads
How to Cite
1.
Rana S, Sivaperumal R. In-Silico evaluation of Anti-Leishmanial compounds of selected pharmacophore. JDDT [Internet]. 15Dec.2018 [cited 18Feb.2020];8(6-s):227-9. Available from: http://jddtonline.info/index.php/jddt/article/view/2119